Serum HE4 and CA125 are shown to have relatively high expression levels in most patients with advanced ovarian cancer, which can be reduced effectively in those who respond well to surgical treatment; however, the reduced serum HE4 and CA125 expression can be reversed if the surgical procedure fails or ovarian cancer relapses. Here, WFDC2 is linked to ovarian carcinoma.